{"entity":{"id":"nct04547504","kind":"trial","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","aka":["PERSEE"],"tldr":"A phase 3 trial of pembrolizumab in lung cancer, run by University Hospital, Brest, active but no longer recruiting.","summary":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % is a phase 3, randomised interventional study registered as NCT04547504 by University Hospital, Brest, with a registry enrolment figure of 349 participants, started 2020-12-22 and due to reach its primary completion in 2025-12-22. Interventions recorded: Pembrolizumab; Pembrolizumab and Chemotherapy drugs. Conditions listed: Non-small-cell Lung Cancer. Primary outcome: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed NSCLC\". Sites: France. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04547504","url":"https://clinicaltrials.gov/study/NCT04547504"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04547504","phase":"3","setting":"Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%","sponsor":"University Hospital, Brest","enrolled":349,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04547504/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}